Physician profile
Ryan Barrett
NPI 1982994844
$6,775.59
in general payments reported to CMS, 2019-2025
21 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $188 · 2021: $750 · 2022: $748 · 2023: $930 · 2024: $770 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796 · Travel and Lodging: $393 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.10 |
| Travel and Lodging | $393.31 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,060.36 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $927.08 | 2022-2025 | Stellaris, Ic-8 Apthera Iol, Envista Envy Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $596.39 | 2019-2021 | |
| Alcon Vision LLC | $569.49 | 2019-2025 | Hydrus Microstent, Voyager Dslt, Eysuvis |
| Harrow Eye, LLC | $561.64 | 2024-2025 | Iheezo |
| Novartis Pharmaceuticals Corporation | $539.82 | 2019-2023 | |
| Glaukos Corporation | $501.76 | 2019-2025 | Idose, Photrexa Viscous and Photrexa |
| Rxsight INC | $484.72 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $364.68 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $301.97 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $131.35 | 2019 | |
| Kala Pharmaceuticals, INC. | $128.99 | 2021-2022 | |
| New World Medical,INC. | $128.79 | 2022 | |
| Aerie Pharmaceuticals, INC. | $114.10 | 2019 | |
| Sun Pharmaceutical Industries INC. | $111.50 | 2023-2025 | Cequa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.57 | 2022-2025 | |
| Ivantis, INC | $64.80 | 2019-2021 | |
| Horizon Therapeutics Plc | $55.97 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $18.96 | 2024 | Rayner Cataract Set 1, Rayone Aspheric, Rayone Emv |
| Dompe US, INC. | $15.65 | 2024 | Oxervate |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.